Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNVZDT)

Drug Name

ISIS-FGFR4 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Obesity	5B81	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting FGFR4 messenger RNA (FGFR4 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
FGF401	DMWEJ0C	Hepatocellular carcinoma	2C12.02	Phase 1/2	[3]
H3B-6527	DMAYTRK	Hepatocellular carcinoma	2C12.02	Phase 1	[3]
BLU-554	DM27J3D	Hepatocellular carcinoma	2C12.02	Phase 1	[3]
PD-0183812	DMWYP86	Retinoblastoma	2D02.2	Terminated	[4]
Ro-4396686	DM5DMCH	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT02476019) A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients.
2	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16.
5	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.